Sirukumab, which selectively binds to interleukin (IL)-6, was found effective for the treatment of active rheumatoid arthritis, particularly for inhibiting damage, in a phase III trial. By week 52, no radiographic progression was seen in 59 percent of the 50-mg group and in 64.2 percent of the 100-mg group.

Click here for more.